Kenta to develop antibody for staphylococcus bacteria

Kenta Biotech has entered into an agreement with Rentschler Biotechnologie for the development of a

Using Kenta's hybridoma cell line, Rentschler will develop a manufacturing process for the former's KBSA301 antibody using single-use bioreactor technology for the first time.

KBSA301 is a fully-human IgG antibody designed to treat infections caused by MRSA, a type of bacteria that can become resistant to certain antibiotics, including methicillin, oxacillin, penicillin and amoxicillin. KBSA301 has shown in several preclinical animal models that the antibody is effective in treating severe Staphylococcus aureus infections.